Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $42 price target on the stock.
December 14, 2023 | 5:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst reaffirms an Overweight rating on ACADIA Pharmaceuticals with a steady price target of $42, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst like Charles Duncan suggests a bullish sentiment on ACADIA Pharmaceuticals. The maintained price target of $42 implies that the analyst believes the stock has the potential to reach or exceed this level in the short term, which could positively influence investor confidence and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100